Potential Antiviral Drug Intervention for Treatment of COVID-۱۹: A Minireview

In this minireview, we evaluated the studies that underlie the usage and suggestion of antivirals forthe treatment of coronavirus disease ۲۰۱۹ (COVID-۱۹). Until now, there has been no known curativetreatment for COVID-۱۹. However, many clinical trials have used antiviral medicines including remdesivir,lopinavir (LPV), ritonavir (RTV), ribavirin, favipiravir (FPV), oseltamivir, umifenovir, and nitazoxanide.Using remdesivir in patients with severe COVID-۱۹ has improved respiratory symptoms, making theremdesivir one of the specific drugs suggested for the treatment of severe COVID-۱۹. It has been shownthat triple antiviral therapy (LPV, RTV, and ribavirin) can improve symptoms and consequently shorten theduration of viral shedding and hospital stay. However, the results of treatment with oseltamivir, umifenovir,and a combination of LPV and RTV were not different from the results of treatment with standard carein the time to clinical improvement. FPV showed better therapeutic responses to COVID-۱۹ in termsof disease progression and viral clearance. Future clinical studies should evaluate the effect of antiviralagents for the treatment of COVID-۱۹ outbreak. Therefore, it is suggested that highly active antiviral drugsshould be used in combination with other therapeutic approaches for the treatment of COVID-۱۹.

کلیدواژه ها:

COVID-۱۹ ، Antiviral ، Remdesivir ، favipiravir ، Oseltamivir